NCT07567833RecruitingPhase 4
Longitudinal Study of Retinal Function in Eyes Treated for Diabetic Macular Edema With Anti-VEGF Agents
Source: ClinicalTrials.gov · Last updated 23 Oct 2026
Brief summary (registry, in English)
A considerable hurdle to the development of novel, more effective therapies for diabetic retinal disease is the limited number of primary endpoints available for use in regulatory trials. Current endpoints necessitate long trial durations and a greater number of participants to show efficacy. Thus, a better understanding of the structural and functional changes in the retina occurring in people with diabetes is essential for developing primary endpoints and validating surrogate and clinical endpoints.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 9 Feb 2026
- Start date
- 31 Jul 2026
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Jaeb Center for Health Research
- Diseases
- Diabetic eye disease
- NCT number
- NCT07567833
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 100
- From 31 Jul 2026 to the primary completion date, 31 Dec 2027
- 8 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous treatment of any kind for diabetic retinopathy or DME
- Intraocular surgery (including cataract surgery) within 4 months prior to enrollment or anticipated within the next 6 months
Other illness
- Ocular or systemic condition, aside from diabetes mellitus (DM), that is likely to affect the assessment of DRSS, DME, or the functioning of the neural retina.
- Any condition that may preclude adequate imaging of the macula (e.g. dense cataract or other media opacity, ptosis)
- History of rhegmatogenous retinal detachment or macular hole
- History of vitrectomy
Who the study is looking for
- Age ≥18 years
- Diagnosed with Type 1 or Type 2 diabetes
- Best corrected visual acuity 20/320 or better (Snellen) (≥24 ETDRS letters)
- At least 1 eye with CI-DME requiring treatment
- Able and willing to provide informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (8)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Southeast Retina Center, P.C. Coordinator of this site? Confirm its status | Augusta | United States | Recruiting |
| Retina Consultants of Texas Coordinator of this site? Confirm its status | Beaumont | United States | Recruiting |
| Boston Medical Center Corporation Coordinator of this site? Confirm its status | Boston | United States | Recruiting |
| Henry Ford Health System Coordinator of this site? Confirm its status | Detroit | United States | Recruiting |
| Retina Consultants of Southern California Coordinator of this site? Confirm its status | Huntington Beach | United States | Recruiting |
| Retina-Vitreous Consultants, Inc. Coordinator of this site? Confirm its status | Monroeville | United States | Recruiting |
| Mayo Clinic Coordinator of this site? Confirm its status | Rochester | United States | Recruiting |
| Pittsburgh Clinical Trial Consortium Coordinator of this site? Confirm its status | Sewickley | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.